Life Sciences Dealmaking Symposium 2024

From our many conversations and attendance of the many discussions, here are the key takeaways in the life sciences and Medtech markets you should consider:

1. Pharma Deal activity is up, deal quantity is down

This could very well be an appetite for continued investment, but a lack of appetite for risk, resulting in a shifting of investment toward more mature opportunities.

2. GLP-1 Drug competition is heating up

This fact could have a myriad of follow-on effects, including a significant impact on how diabetes and obesity are monitored and treated. For example, what will the impact be on home testing equipment for blood sugar?

3. Anticipated Economic Policy Changes could impact investments and innovation

New trade policy could disrupt existing supply chains and take capital away from investments in order to maintain existing revenue streams

• • Improving Public Health with Affordable Disease Tests

• • Point-of-Care Diagnostic Provides Lab-Quality Results in Minutes

• • More About In Vitro Diagnostics at Boston Engineering

• • More about Surgical Robotics at Boston Engineering

• • More about Patient Monitoring at Boston Engineering

• • More about Women’s Health @ Boston Engineering

• • More about Boston Engineering Medical Market Expertise

• • More about the Boston Engineering Centers of Excellence

• • More About Boston Engineering Solutions

• • More about Boston Engineering’s Insights and Thought Leadership